Wendy Lam, BSc. (Pharm), MD, FRCPC

Hematologist and Medical Oncologist
Burnaby Hospital Regional Cancer Center
Director, BC Community Oncology Trialists
Burnaby, BC

Dr. Wendy Lam is a hematologist and medical oncologist at the Burnaby Hospital Regional Cancer Centre.

She received her B.Sc (Pharmacy) at Dalhousie University and her MD from University of British Columbia. She then completed her Internal Medicine residency at UBC and Hematology fellowship at McMaster University.

She is the Founding Director of the British Columbia Community Oncology Trialists (BC Cot), which is a collaborative group of oncologists and hematologists involved in clinical research.

Her other interests include education of patients through meeting with patient groups. She has also been instrumental in organizing meetings for continued medical education.

She is Director of the Society of Hematology and Oncology of BC at British Columbia Medical Association.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.

Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Laurie H. Sehn, MD, MPH

Clinical Professor
Centre for Lymphoid Cancer,
British Columbia Cancer Agency and
University of British Columbia,
Vancouver, BC

Dr. Laurie Sehn is currently Clinical Professor with the British Columbia Cancer Agency and University of British Columbia, Canada. She has been a medical oncologist and clinical investigator at the BC Cancer Agency since 1998, and is currently the Chair of the Lymphoma Tumour Group. Dr. Sehn graduated from McGill Medical School, Montreal, Canada and received her training in Internal Medicine at Columbia Presbyterian Medical Center, Columbia University, New York, USA. She was trained in Haematology-Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard University, Boston, and received a Masters of Public Health degree from Harvard School of Public Health, Harvard University.

Prior to returning to Canada, she spent a year at the Dana-Farber Cancer Institute attending on the Bone Marrow Transplant service. Dr. Sehn is Chair of the medical advisory board for the International Lymphoma Coalition. She has also served as a member of the editorial board of Journal of Clinical Oncology and Leukemia Lymphoma, and is currently an Associate Editor for Blood. Dr. Sehn also serves as co-chair of the Lymphoma Site of the Canadian Cancer Trials Group.

Simon Yu, MD, FRCPC

Hematologist and Medical Oncologist
Burnaby Hospital Regional Cancer Center
Director, BC Community Oncology Trialists
Burnaby, BC

Dr. Simon Yu is a medical oncologist practicing at Burnaby Hospital and Ridge Meadows Hospital in British Columbia.  He completed his internal medicine and medical oncology residency at University of British Columbia and BC Cancer Agency.  His practice consists of almost all solid tumors and select hematologic malignancies.

Andrew Bang, MPH MD FRCSC

Radiation Oncologist, BC Cancer
Vancouver, BC

Dr. Andrew Bang is a radiation oncologist at BC Cancer Vancouver. He completed his residency at the University of Ottawa and fellowships in SABR and combination IO therapies at Princess Margaret Cancer Center and Dana-Farber Cancer Institute.

Christopher Hillis, MD MSc FRCPC

Hematologist, Juravinski Hospital and Cancer Centre
Associate Professor, Department of Oncology, McMaster University
Vice President of Oncology, Hamilton Health Sciences
Hamilton, ON

Dr. Chris Hillis is a malignant hematologist at the Juravinski Cancer Centre, Associate Professor at McMaster University, and Vice President of Oncology at Hamilton Health Sciences. He completed an MSc in Quality Improvement and Patient Safety and trained as a Quality Scholar with the U.S. Department of Veterans Affairs, grounding his leadership approach in evidence-based improvement science.
Clinically, Dr. Hillis specializes in CLL and MPNs and leads a CIHR-funded research program focused on patient-relevant trial outcomes. He is President of the Canadian Hematology Society and a national leader in cancer care quality and system redesign.

Cheryl Ho, MD, FRCPC(C)

Clinical Associate Professor
University of British Columbia
Medical Oncologist
British Columbia Cancer
Vancouver, BC

Cheryl Ho, MD is a medical oncologist at BC Cancer and Clinical Associate Professor at the University of British Columbia. Her clinical practice focuses on thoracic and head & neck malignancies. Dr. Ho evaluates the impact of therapies proven in clinical trials in the real world through population-based analysis. Her current focus is on developing a learning health care system with a real-world data evidence-generation framework to inform healthcare decision-makers.

Nathalie LeVasseur MD, BSc, FRCPC

Medical Oncologist, BC Cancer
Assistant Clinical Professor, Department of Medicine, UBC
Vancouver, BC

Nathalie LeVasseur is an Assistant Clinical Professor in the Department of Medicine, Division of Medical Oncology at the University of British Columbia in Vancouver since October 2019. She received her medical degree in 2013 and completed her internal medicine residency at the University of Ottawa. She subsequently pursued a residency in medical oncology at the University of British Columbia and served as chief resident before completing a breast cancer clinical and research fellowship at the BC Cancer Agency.

Dr. LeVasseur is the current chair of Breast Systemic Policy in BC, the co-lead of the Breast Cancer Clinical Trials Unit in Vancouver and serves on the CCTG IND Executive Committee. Her research focus is in the development of personalized oncology with informative tools, genomics and transcriptomics. Additionally, the improvement of patient outcomes and survivorship is an area of ongoing research interest.

Dr. LeVasseur is a Fellow of the Royal College of Physicians and Surgeons of Canada. She holds professional memberships with the American Society of Clinical Oncology, Canadian Association of Medical Oncology, among others. She has received academic achievement awards including a Conquer Cancer ASCO Merit Award, NOYCIA Award and a Coltman Scholars Award.

Mehrnoosh Pauls, MD

Medical Oncologist, Lions Gate Hospital
North Vancouver, BC

Dr. Mehrnoosh Pauls finished breast cancer fellow with Dr. Chia in the Division of Medical Oncology, BC Cancer, Vancouver Cancer Centre. She initially started her medical career in the Leaders of Medicine program at the University of Calgary, completing her MD/MSc in Cancer Biology in 2015. Dr. Pauls completed her internal medicine training at Dalhousie University, followed by medical oncology training at the University of Ottawa. She then worked a year at Saskatoon Cancer Center (SCA) as a full-time medical oncologist taking the role of neuroendocrine tumour site lead. During her one-year staff position, she was the primary lead oncologist for setting up the peptide receptor radionuclide therapy (PRRT) program, a target molecular target therapy used to treat NET at SCA. Currently, Dr. Pauls is working as medical oncologist at Lions Gate Hospital and BC cancer North Vancouver

Devin Schellenberg, MD, FRCS(C)

Clinical Associate Professor – UBC
Department Head, Radiation Oncology
BC Cancer – Surrey Centre

Dr. Devin Schellenberg completed medical school and Residency at the University of BC and University of Toronto. He went onto a Fellowship at Stanford University and has been the Department Head of Radiation Oncology at the BC Cancer Surrey Centre for the past 4 years. He chairs the Lung Radiation Oncology working group with CCTG and is a founding member of CAPRI (Canadian Pulmonary Radiotherapy Investigators Group).

He has been a leader in BC Cancer’s Stereotactic Ablative Body Radiotherapy (SABR) programs and his current research efforts focus on how radiation can alter the course of metastatic disease and (outside of cancer) whether radiation is able to treat heart arrhythmias.